Hikma Pharmaceuticals Plc Blocklisting Interim Review (2457C)
January 15 2015 - 5:04AM
UK Regulatory
TIDMHIK
RNS Number : 2457C
Hikma Pharmaceuticals Plc
15 January 2015
Block Listing of Shares
Hikma PharmaceuticalsPLC
LONDON, 15 January 2015 - The Board of Hikma Pharmaceuticals PLC
("Hikma") (LSE: HIK) (NASDAQ: HIK), announces that it has made a
block listing application to the Financial Conduct Authority and
the London Stock Exchange plc for a total of 500,000 ordinary
shares of 10p each in the capital of the Company to be admitted to
the Official List of the UK Listing Authority. It is expected that
admission will be granted on 16 January 2015.
The shares, when issued, will be issued fully paid and rank pari
passu in all respects with the existing issued ordinary shares of
the Company. The shares will be issued pursuant to the vesting of
shares under the Hikma Pharmaceuticals PLC 2005 Long Term Incentive
Plan and the 2009 Management Incentive Plan (the "Plans").
Participants in the Plans have or will become entitled to these
shares following the vesting of the shares.
- ENDS -
Enquiries
Hikma Pharmaceuticals PLC
Peter Speirs
Company Secretary +44 20 7399 2760
About Hikma
Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group
focused on developing, manufacturing and marketing a broad range of
both branded and non-branded generic and in-licensed products.
Hikma's operations are conducted through three businesses:
"Branded", "Injectables" and "Generics" based primarily in the
Middle East and North Africa ("MENA") region, where it is a market
leader, the United States and Europe. In 2013, Hikma achieved
revenues of $1,365 million and profit attributable to shareholders
of $212 million.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BLRGMGMMGKFGKZM
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024